Growth Hormone Secretion
Tesamorelin + Ipamorelin
Tesa+Ipa; long-acting GHRH + selective GHRP blend
FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
This Tesamorelin + Ipamorelin entry draws on 3 cited sources published 1998 to 2007. The evidence available is graded FDA-Approved (component) on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
- Drug class
- Growth Hormone Secretion
- Structure
- Co-formulated vial: ~1-2 mg Tesamorelin (44-aa hGHRH analog) + ~2 mg Ipamorelin (pentapeptide)
- Route
- SC injection
- Half-life
- Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
- Evidence tier
- FDA-Approved (component)
- Availability
- Compounding Restricted
Mechanism of action
Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Reported areas of research
Visceral adiposity reduction (Tesamorelin signal); improved sleep and recovery; cleaner side-effect profile than CJC-DAC blends; favoured for HIV-lipodystrophy-adjacent body composition goals
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)
Compared with
Tesamorelin + Ipamorelin has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
- Tesamorelin + Ipamorelin vs CJC-1295
- Tesamorelin + Ipamorelin vs CJC-1295 + Ipamorelin
- Tesamorelin + Ipamorelin vs GHRP-2
- Tesamorelin + Ipamorelin vs GHRP-6
- Tesamorelin + Ipamorelin vs Hexarelin
- Tesamorelin + Ipamorelin vs Hulk Stack
- Tesamorelin + Ipamorelin vs Ipamorelin
- Tesamorelin + Ipamorelin vs MK-677
- Tesamorelin + Ipamorelin vs Sermorelin
- Tesamorelin + Ipamorelin vs Tesamorelin
Frequently asked questions
What dosing is reported for Tesamorelin + Ipamorelin in research literature?
Published peptide research reports the following dosing approach for Tesamorelin + Ipamorelin: 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off. This is a research reference, not a clinical recommendation.
How is Tesamorelin + Ipamorelin administered in research?
Tesamorelin + Ipamorelin is administered via the following routes in published studies: SC injection.
What is the reported half-life of Tesamorelin + Ipamorelin?
The reported half-life of Tesamorelin + Ipamorelin is Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs.
Is Tesamorelin + Ipamorelin FDA-approved?
Not as a combination. Tesamorelin + Ipamorelin combines compounds of which only one is FDA-approved, and the combination itself has no FDA approval. PeptideHelper.org catalog status: Compounding Restricted.
What level of evidence supports Tesamorelin + Ipamorelin?
The current evidence base for Tesamorelin + Ipamorelin is best characterised as: FDA-Approved (component). See the methodology page for the full evidence-tier rubric.
What side effects are reported for Tesamorelin + Ipamorelin?
Known concerns reported in the literature for Tesamorelin + Ipamorelin include: Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive). Always consult a qualified clinician before any human use.
Is there anyone who should not use Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin is FDA-approved, but no contraindications section was retrievable from its current label, so none is reproduced here. Consult the prescribing information and a qualified clinician before any human use.
How does Tesamorelin + Ipamorelin work?
The mechanism of action reported for Tesamorelin + Ipamorelin in the literature: Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover..
What is Tesamorelin + Ipamorelin studied for?
Tesamorelin + Ipamorelin has been studied in the published literature for: Visceral adiposity reduction (Tesamorelin signal); improved sleep and recovery; cleaner side-effect profile than CJC-DAC blends; favoured for HIV-lipodystrophy-adjacent body composition goals. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin is classified as: FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Also known as: Tesa+Ipa; long-acting GHRH + selective GHRP blend.
Drug class
- GHRH peptides, see all peptides tagged GHRH.
- GHRP peptides, see all peptides tagged GHRP.
- GH-secretagogue peptides, see all peptides tagged GH-secretagogue.
Research focus area
All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.
Primary sources
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…